Valentino joins Alpharma
This article was originally published in The Tan Sheet
Executive Summary
Michael Valentino steps into newly created role of president & COO of Global Human Pharmaceuticals and exec VP of firm effective Oct. 15. He reports to Alpharma President & CEO Ingrid Wiik, who says Valentino will help to develop firm's "global growth opportunities by creating and expanding key strategic alliances [and] developing a strong global new product pipeline." Valentino most recently served as Novartis Consumer Health global head/exec VP and also was chairman of CHPA's board (1"The Tan Sheet" Jan. 7, 2002, p. 3)...
You may also be interested in...
Novartis Consumer Health Changes Leave CHPA Without A Chair
Novartis exec Michel Orsinger has taken the reigns as head of the firm's consumer health global OTC division, effective Jan. 1
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.